Ionis Pharmaceuticals Stock Today
| IONS Stock | USD 42.45 0.61 1.46% |
Performance0 of 100
| Odds Of DistressLess than 29
|
Ionis Pharmaceuticals is selling for under 42.45 as of the 25th of April 2024; that is 1.46 percent increase since the beginning of the trading day. The stock's lowest day price was 42.45. Ionis Pharmaceuticals has about a 29 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for Ionis Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of March 2024 and ending today, the 25th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 17th of May 1991 | Category Healthcare | Classification Health Care |
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California. Ionis Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 145.75 M outstanding shares of which 9.52 M shares are currently shorted by private and institutional investors with about 9.08 trading days to cover. More on Ionis Pharmaceuticals
Moving against Ionis Stock
| 0.76 | LLY | Eli Lilly Earnings Call This Week | PairCorr |
| 0.75 | VKTX | Viking Therapeutics Potential Growth | PairCorr |
| 0.74 | ELEV | Elevation Oncology Earnings Call This Week | PairCorr |
| 0.67 | NRSNW | NeuroSense Therapeutics | PairCorr |
| 0.65 | XFOR | X4 Pharmaceuticals Earnings Call This Week | PairCorr |
| 0.44 | BMY | Bristol Myers Squibb Earnings Call Today | PairCorr |
| 0.43 | HEPA | Hepion Pharmaceuticals Financial Report 10th of May 2024 | PairCorr |
Ionis Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Ionis Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Ionis Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary, Ionis Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Ionis Pharmaceuticals' managers, analysts, and investors.
Environment Score | Governance Score | Social Score |
| Chairman | Stanley Crooke | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Biotechnology, Dow Jones Biotechnology, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Excise Tax Activities | Animal Testing | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Ionis Pharmaceuticals report their recommendations after researching Ionis Pharmaceuticals' financial statements, talking to executives and customers, or listening in on Ionis Pharmaceuticals' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Ionis Pharmaceuticals. The Ionis consensus assessment is calculated by taking the average forecast from all of the analysts covering Ionis Pharmaceuticals. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Ionis Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Ionis Pharmaceuticals is not in a good financial situation at this time. It has a very high odds of going through financial crisis in May. Financial strength of Ionis Pharmaceuticals is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ionis Pharmaceuticals' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Ionis Pharmaceuticals' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. Ionis Pharmaceuticals' bond ratings measure its overall creditworthiness, which in many ways corresponds to the cost of borrowing for an issuer. These ratings assign a letter grade to all of Ionis Pharmaceuticals' outstanding corporate bonds that indicate their credit quality. We use reports published by private self-sufficient rating services such as Standard & Poor's or Fitch Ratings Inc. to evaluate a bond issuer's financial strength or its ability to pay a bond's principal and interest. Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Ionis Pharmaceuticals' financial leverage. It provides some insight into what part of Ionis Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ionis Pharmaceuticals (IONS) is traded on NASDAQ Exchange in USA. It is located in 2855 Gazelle Court, Carlsbad, CA, United States, 92010 and employs 927 people. Ionis Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 6.16 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Ionis Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Ionis Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Ionis Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 145.75 M outstanding shares of which 9.52 M shares are currently shorted by private and institutional investors with about 9.08 trading days to cover.
Ionis Pharmaceuticals currently holds about 2.04 B in cash with (307.51 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 14.36.
Check Ionis Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationIonis Pharmaceuticals secures a total of 145.75 Million outstanding shares. The majority of Ionis Pharmaceuticals outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Ionis Pharmaceuticals to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Ionis Pharmaceuticals. Please pay attention to any change in the institutional holdings of Ionis Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Ionis Ownership Details
Ionis Stock Price Odds Analysis
Attributed to a normal probability distribution, the odds of Ionis Pharmaceuticals jumping above the current price in 90 days from now is about 80.19%. The Ionis Pharmaceuticals probability density function shows the probability of Ionis Pharmaceuticals stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Ionis Pharmaceuticals has a beta of 0.6995. This usually indicates as returns on the market go up, Ionis Pharmaceuticals average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Ionis Pharmaceuticals will be expected to be much smaller as well. Additionally, ionis Pharmaceuticals has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Ionis Pharmaceuticals to move above the current price in 90 days from now is about 80.19 (This Ionis Pharmaceuticals probability density function shows the probability of Ionis Stock to fall within a particular range of prices over 90 days) .
Ionis Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Ionis Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Ionis Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Ionis Pharmaceuticals' value.| Instituion | Recorded On | Shares | |
| Tweedy, Browne Co Llc | 2023-12-31 | 3.5 M | |
| Macquarie Group Ltd | 2023-12-31 | 3.1 M | |
| Geode Capital Management, Llc | 2023-12-31 | 2.3 M | |
| Orbimed Advisors, Llc | 2023-12-31 | 2.1 M | |
| Ark Investment Management Llc | 2023-12-31 | 1.9 M | |
| Farallon Capital Management, L.l.c. | 2023-12-31 | 1.6 M | |
| Adage Capital Partners Gp Llc | 2023-12-31 | 1.4 M | |
| Charles Schwab Investment Management Inc | 2023-12-31 | 1.3 M | |
| Deep Track Capital, Lp | 2023-12-31 | 1.2 M | |
| Fmr Inc | 2023-12-31 | 21.5 M | |
| Vanguard Group Inc | 2023-12-31 | 14.2 M |
Ionis Pharmaceuticals Historical Income Statement
Ionis Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting Ionis's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Ionis Pharmaceuticals revenue and expense. Ionis Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Ionis Pharmaceuticals' Research Development is comparatively stable compared to the past year. Selling General Administrative is likely to gain to about 244.2 M in 2024, despite the fact that EBIT is likely to grow to (328.1 M). View More FundamentalsIonis Stock Against Markets
Picking the right benchmark for Ionis Pharmaceuticals stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Ionis Pharmaceuticals stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Ionis Pharmaceuticals is critical whether you are bullish or bearish towards Ionis Pharmaceuticals at a given time. Please also check how Ionis Pharmaceuticals' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Ionis Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Commodity Directory Now
Commodity DirectoryFind actively traded commodities issued by global exchanges |
| All Next | Launch Module |
Ionis Pharmaceuticals Corporate Directors
Ionis Pharmaceuticals corporate directors refer to members of an Ionis Pharmaceuticals board of directors. The board of directors generally takes responsibility for the Ionis Pharmaceuticals' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Ionis Pharmaceuticals' board members must vote for the resolution. The Ionis Pharmaceuticals board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Joseph Klein | Independent Director | Profile | |
| Michael Hayden | Director | Profile | |
| Spencer Berthelsen | Independent Director | Profile | |
| Frederick Muto | Independent Director | Profile |
How to buy Ionis Stock?
Before investing in Ionis Pharmaceuticals, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Ionis Pharmaceuticals. To buy Ionis Pharmaceuticals stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Ionis Pharmaceuticals. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Ionis Pharmaceuticals stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Ionis Pharmaceuticals stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Ionis Pharmaceuticals stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Ionis Pharmaceuticals, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Ionis Stock please use our How to Invest in Ionis Pharmaceuticals guide.
Already Invested in Ionis Pharmaceuticals?
The danger of trading Ionis Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Ionis Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Ionis Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Ionis Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Ionis Pharmaceuticals is a strong investment it is important to analyze Ionis Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ionis Pharmaceuticals' future performance. For an informed investment choice regarding Ionis Stock, refer to the following important reports: Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ionis Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Ionis Stock please use our How to Invest in Ionis Pharmaceuticals guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Complementary Tools for Ionis Stock analysis
When running Ionis Pharmaceuticals' price analysis, check to measure Ionis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ionis Pharmaceuticals is operating at the current time. Most of Ionis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ionis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ionis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ionis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |
Is Ionis Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ionis Pharmaceuticals. If investors know Ionis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ionis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.44) | Earnings Share (2.56) | Revenue Per Share 5.501 | Quarterly Revenue Growth 1.136 | Return On Assets (0.08) |
The market value of Ionis Pharmaceuticals is measured differently than its book value, which is the value of Ionis that is recorded on the company's balance sheet. Investors also form their own opinion of Ionis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ionis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ionis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ionis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ionis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ionis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ionis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.